VANCOUVER and SYDNEY, New South
Wales, Feb. 20, 2018 /CNW/ - PUF Ventures Inc. ("PUF" or the
"Company") (CSE: PUF) (Frankfurt: PU3) (OTCPK: PUFXF), an advanced Access to Cannabis for Medical Purposes
Regulations ("ACMPR") license applicant, and its strategic partner MYM Nutraceuticals (CSE: MYM) are pleased to announce a joint
venture agreement between Southern Cross University and Solaris Nutraceuticals to commit to the development of hemp and medicinal
cannabis products in the NSW Northern Rivers region that will enhance animal and human health. The agreement will pave the way
for a flourishing industry built on the medicinal value of cannabis.
Vice-Chancellor Professor Adam Shoemaker said the agreement was a great step forward not just
for the region, but also for consumers.
"Universities have a vital role to play as catalysts for diversification and development – creating new opportunities through
21st century industries," said Professor Shoemaker. "Legalized cannabis products are already playing a critically
important role in delivering medicines, and through innovation, have the potential to improve the lives of millions more through
new medical applications and nutrition. This agreement is a great example of Southern Cross University's commitment to engaging
with industry and the community, so that we can create an environment for discovery and commercial development, driving changes
in our back yard that can translate into benefits around the world."
Professor Shoemaker signed the agreement with Mr. Michael Horsfall, CEO of Solaris
Nutraceuticals, committing to a new approach that brings together the University's internationally-recognized expertise in
medicinal cannabis research with the corporate capabilities of Solaris Nutraceuticals.
The University's Lismore campus is equipped with high-security research laboratories where
researchers work with the world's most diverse collection of cannabis seed and has already established an international
reputation for botanical research. The decision of Solaris to establish a new medicinal cannabis plant in Casino, just a half
hour drive from Lismore, has underscored the potential of this collaboration to yield
substantial outcomes.
"This is an exciting opportunity not just for Solaris Nutraceuticals, but also for the Northern Rivers region," said Mr.
Horsfall. "The project will deliver around 300 direct jobs and make a significant impact to the local economy and raise the
socio-economic profile of the Northern Rivers region. On Friday, February 2, 2018, this project
received grant funding of $2.5 million from the Australian Government as part of the Regional Jobs
Investment Packages program (RJIP), a grant initiative that was made available by the Department of Industry, Innovation and
Science. This is a significant step forward for our project and we are very appreciative of the support we have received
from federal, state and local governments. Solaris Nutraceuticals will work with the University to identify opportunities to
improve the properties and quality of medicines that can be derived from cannabis. These new collaborations hold tremendous
potential and we are excited to be working towards a strong future together with Southern Cross."
About Southern Cross University
Australia's engaged university, Southern Cross, has maximized its impact by forging close
partnerships with industry, communities and research partners around the world. With campuses in Lismore, Coffs Harbour and the Gold Coast, Southern Cross was founded in
1994 and is already ranked by Times Higher Education (THE) in the top 500 universities in the world, including ranking in the top
300 for life sciences.
About Solaris Nutraceuticals Inc.
Solaris Nutraceuticals is an innovative medical technology company headquartered in Sydney,
Australia. The Company is owned by PUF Ventures Inc. (CSE: PUF), MYM Nutraceuticals Inc. (CSE: MYM), Chrome Holdings of
Australia and private investors. It has submitted applications and plans with Australia's Office of Drug Control to build a 1.2 million square-foot greenhouse facility with cannabis
production space and a medical research center in the Northern Rivers Region of New South Wales,
Australia. Solaris' corporate mission is to deliver environmentally friendly, sun grown medicinal grade cannabis and to
develop medicines and treatments for pain management and other medical conditions. The company's focus is on innovations that
promote, support and deliver improvements in the quality, consistency and cost of medicines to our clients. For more information,
visit www.solarisnutraceuticals.com.
About PUF Ventures Inc.
PUF Ventures Inc. is a growth oriented and diversified company focused on the international cannabis industry. It has
ownership in several cannabis companies: AAA Heidelberg, Solaris Nutraceuticals Pty Ltd., and Natures Hemp Corp., and is actively
pursuing other opportunities within the industry. PUF has an option to purchase 100% of AAA Heidelberg Inc., a private
Ontario company and advanced applicant for an ACMPR license. Solaris Nutraceuticals is building
the largest medical cannabis greenhouse in the Southern Hemisphere. For more information please visit: www.puf.ca.
ON BEHALF OF THE BOARD OF DIRECTORS
Derek Ivany
President & CEO
No stock exchange or securities regulatory authority has reviewed or accepted responsibility for the adequacy or accuracy
of this release.
Some of the statements contained in this release are forward-looking statements, such as estimates and statements that
describe the Issuer's future plans, objectives or goals, including words to the effect that the Issuer or management expects a
stated condition or result to occur. Since forward-looking statements address future events and conditions, by their very nature,
they involve inherent risks and uncertainties.
SOURCE PUF Ventures
View original content with multimedia: http://www.newswire.ca/en/releases/archive/February2018/20/c2943.html